Kornimate/medical-research-clean huggingface dataset:
selection of allogeneic hematopoietic cell donors based on kir and hla genotypes

Conditions: Leukemia

Summary: this study tests whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. stem cell donors are "matched" based on genes called human leukocyte antigens (hla). currently, donors are selected largely on the basis of hla gene typing alone. there is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (kir) may protect aml patients from having their leukemia return after a transplant. in this study, the best hla matched donors will be tested for the kir genes. if there is more than 1 donor available, a recommendation will be provided to study doctors as to which donors have potentially favorable kir genes. the study doctors may or may not choose to use this donor for transplant or not based on his/her own judgment. transplant care will not change otherwise as a result of this study. this study is being done to demonstrate that aml patients who have donors with specific kir and hla genes will have a better outcome following transplant.


Eligibility criteria:
inclusion criteria: recipient * persons of all ages are eligible for this study. * patient must have diagnosis of acute myelogenous leukemia (aml) at msk or a collaborating treating institution. patients with de novo aml or aml with preceding myelodysplastic syndrome (mds) are eligible. * patient must be a potential candidate for an unrelated transplantation procedure at the time of enrollment even though patient may not be eligible for transplantation in the future due to relapse or presence of co-morbidity(ies). * an unrelated donor does not need to be identified at the time of enrollment. if an hla-compatible unrelated donor is not identified for the patient, the patient will be removed from the study. exclusion criteria: * recipients with an available sibling donor matched at hla-a, hla-c, and hla-drb1 (excluding identical twin siblings). * patients for whom post-transplant treatment is planned are not excluded from enrollment. * patients with prior allogeneic hematopoietic cell transplantation for aml. note: patients who have undergone prior hematopoietic cell transplantation for a diagnosis other than aml are still eligible for this study.

Keywords: allogeneic hematopoietic cell donors kir and hla genotypes 15-059
the effect of heparinization due to lbw

Conditions: Heparin; Heparin Overdose; Bleeding

Summary: high dose heparin regimens are required in cardiac surgery under cardiopulmonary bypass (cpb) and this may increase postoperative bleeding. the aim of this study is to evaluate the effect of heparin dose calculated according to lean body weight on intraoperative and postoperative bleeding.

patients with preoperative demographic data such as age, gender, body weight, height, and additional disease, medications, previous surgery, preoperative htc / hb values were recorded in the operation room without medical premedication. standard anesthesia induction was performed after arterial cannulation and peripheral venous route. patients were randomly divided into two groups: 400 iu heparin / kg (group i) and 400 iu heparin / kg (group ii) according to actual body weight and lean body weight respectively before cpb. before and after heparin administration, cpb entry and act (activated clotting time) values were counted every 30 minutes, after cpb exit and protamine. in both groups, supplemental heparin was administered when there was a failure to reach the pre-cpb target act value of 400 sec. hemodynamic data and transfusion requirements were recorded during the operation. patient's intraoperative cpb and crossover times, postoperative drainage volume and blood transfusion requirement were recorded.

Eligibility criteria:
inclusion criteria: * 18-65 years old, first time valve surgeries which was done on-pump. exclusion criteria: * revision valve surgeries * patients with coagulation deficits

Keywords: heparin heparin antagonists cardiac surgery active clotting time
urdu translation of pediatric version of eating assessment tool

Conditions: Cerebral Palsy

Summary: dysphagia encompasses challenges encountered during the many stages of swallowing, including the oral phase, commencement of the swallow, pharyngeal phase, and esophageal phase. the incidence of pediatric dysphagia is on the rise as a result of advancements in medical care that have led to higher survival rates among infants born prematurely, with low birth weight, and with complex medical disorders. the eating assessment tool (eat-10), consisting of 10 items, was first developed for infant patients. (pedi-eat-10) will be translated into urdu language by using forward backwards translation method. two bilingual speakers expert in both urdu and english languages will assist the researcher in the forward translation of the tool. this final translated version will be then tested for validity and reliability on all participants of the study. the psychometric properties of the tool will be assessed including reliability, internal consistency, and item discrimination.

a mix method approach will be applied 1. forward translation 2. reconciliation of items 3. backward translation 4. review of forward and backward translation 5. pre-testing (cognitive interviewing) 6. validation study the process of translation followed the guidelines in the translation manual. translators translate the pediatric version of eating assessment tool (pedi-eat-10), independently from each other into the urdu language considering the following guidelines: using natural language acceptable to the broader public, performing a clear, simple, and understandable translation, avoiding lengthy and complicated sentences. this will be followed by a backward translation to ensure that the content, from the conceptual point of view, had not been modified in the translation. a native english translator was requested to carry out the back-translation, and all discrepancies were identified and corrected. to show whether all items are easily understood and acceptable to the patients, pretesting the final translated questionnaire will be conducted by administering it to patients with a varying education level. the questions that were not easily understood were discussed and redrafted by a panel of researchers until all interviewees understood all items.

Eligibility criteria:
inclusion criteria: * parents of children diagnosed with eating disorders * age from 3 to 15 years exclusion criteria: * parents with children unable to understand the questionnaire * parents with children who have intellectual disability and any organic type of incontinence, neurological or anatomical problems * parents with who have children severe cognitive decline or dementia * parents with children cannot understand urdu.

Keywords: validation translation eating disorder pedi-eat-10
medical assistance for the procreation and risk of thrombosis.

Conditions: Ovarian Hyperstimulation Syndrome; Cardiovascular Diseases; Embolism and Thrombosis

Summary: this study aims at evaluating clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation. secondary outcomes are : 1) to describe the incidence and risk factors of arterial and venous thrombosis in women undergoing assisted reproductive technology and 2)to identify the incidence and risk factors for ovarian hyperstimulation syndrome in these women

all women undergoing an assisted reproductive tecnology in order to receive an in vitro fertilization in french centers will be included in the study. these women will be followed up until 12 months after ovarian stimulation if they get pregnant or until 3 months if the stimulation does not lead to pregnancy. risk factors for thrombosis and ovarian hyperstimulation syndrome will be collected in each woman. at each visit, women will be asked whether arterial and/or venous thrombosis had occured.

Eligibility criteria:
inclusion criteria: * all women undergoing ovarian stimulation in order to receive in vitro fertilization exclusion criteria: * age\<18 years * women refusing to particpate in the study * no health coverage * women under guardianship * women receiving therapeutic doses of anticoagulation
dna damage and subfertility in males - impact on art outcome

Conditions: Infertility

Summary: a obvational prospective cohort study of men undergoing iui, ivf and icsi treatment in denmark. the aim is to asses the impact of sperm dna damage, measured as dna fragmentation index (dfi), on reproductive outcomes after assisted reproductive technology (art).


Eligibility criteria:
inclusion criteria: * first cycle treatment exclusion criteria: * tesa/pesa, more than one cycle

Keywords: male infertility dna fragmentation index dfi
early hospital discharge program in neonatology

Conditions: Prematurity

Summary: early discharge of premature infants from the neonatal intensive care unit will have substantial benefits: (i) diminish parental stress; (ii) increase parental - child bonding; (iii) diminish medical complications derived from prolonged hospitalization; (iv) reduce cost; (v) increase number of point of attendance disponible for future patients.

extremely premature infants have to remain for very prolonged time in the hospital. as a consequence, difficulties for establishing an adequate parental-infant bonding arise causing a substantial parental stress manifested as anxiety and depression, and increasing the risk of short and longterm consequences (neglect, abuse, maltreatment, abandonment). in addition, prolonged hospital stay will increase the probability of having medical complications (infections, excessive blood tests or image studies) and the cost of staying. once the baby has improved sufficiently early discharge may be given independently of the baby's weight. in order to be successful, caregivers, psychologist and parents have to put forward an established protocol to be able to face satisfactorily this situation. we hypothesize that, with an adequate early discharge program, we could substantially reduce length of hospitalization, cost, and reduce parental stress.

Eligibility criteria:
inclusion criteria: * prematurity * no need for hospital support * parents fulfill sociological score * cooperation of primary care pediatrician exclusion criteria: * active disease * need for hospital intervention * major congenital malformations * chromosomopathies

Keywords: parental stress early discharge anxiety depression neonatal intensive care unit
evidence of neuroplasticity after performing a cognitive task in idiopathic parkinson's disease patients

Conditions: Parkinson Disease

Summary: as seen in previous studies diffusion tensor imaging (dti) mri is able to detect very subtle changes in brain tissue even after a very short timescale of hours resulting from performing a cognitive task and learning, we wish to explore and compare those changes to patients with idiopathic pd (ipd) and see if there are changes in the learning process and can we detect them using widely available noninvasive techniques such as mri.

aim: to utilize high sensitivity dti mri methodology to explore evidence for subtle microstructural brain alterations after performing a cognitive task and to compare those changes in patients with pd to healthy controls of the same age. pd patients and controls will undergo a full cranial mri scan for depiction of anatomy and structural abnormalities (scan duration \~40 min). immediately afterwards the subjects will play a car race computer game (need for speed) for 90 minutes. following the game, the patients will undergo an additional dti mri scan (\~15 minutes).

Eligibility criteria:
inclusion criteria: * patients with ipd based on a clinical diagnosis of pd according to the united kingdom parkinson's disease society brain bank criteria (however patients with a positive family history and symmetrical onset may be included) * healthy subjects should have no known neurological disease matched for age and sex with the study group exclusion criteria: * history of cranial surgery, radiation therapy, tumor, stroke or significant head trauma * history of psychiatric disease (major depression, bipolar affective disorder, schizophrenia) * patients with severe tremor or dyskinesias that may interfere with performance of the mri scan * patients with montreal cognitive assessment (moca) score of 22 or under * contraindications for mri (metal objects: implants/shrapnel/bullet; any electrically, magnetically or mechanically activated implants: cardiac pacemakers/defibrillator, biostimulators, neurostimulators, cochlear implants, hearing aids, insulin pump; claustrophobia) * subjects who are familiar and have played on multiple occasions the computer game "need for speed"

Keywords: parkinson disease mri
omega-3 pufa in prevention of cardiovascular and metabolic diseases (cardmet3)

Conditions: Obesity, Abdominal; Metabolic Syndrome; Cardiovascular Risk Factor

Summary: the study is aimed to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease.

more than four million people in europe (47%) and more than 1.9 million people in european union (eu) (40%) die of cardiovascular diseases (cvd) every year. cvd mortality in eu is 43% in women and 36% in men. in central and eastern europe, much more people die of cvd than in western, northern and southern european countries. the world health organization (who) states that number of deaths in slovakia is much higher than in western european countries, even higher than in v4 countries - slovakia, czech republic, poland and hungary in the first stage of the project fatty acids will be analyzed with the focus on the ratio of omega-6 and omega-3 polyunsaturated fatty acids in fatty food for normal consumption and in nutritional supplements containing omega-3 polyunsaturated fatty acids. in the second phase of the project risk factors of cardiovascular diseases for people without and people with a history of cardiovascular disease will be monitored and compared. there will be monitored and compared a wide range of laboratory markers of clinical biochemistry, immunology, pathological physiology in order to determine cardiovascular risk for men and women in different age categories. the third stage will monitor the effect of natural plant and animal sources and pharmacological nutritional supplements with omega-3 polyunsaturated fatty acids on obesity, metabolic syndrome and cardiovascular risk factors. the aim of this study is to assess the efficacy of animal, plant sources of omega-3 polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and cardiovascular disease.

Eligibility criteria:
inclusion criteria: * for obese participants were bmi≥29, age ≥18 and non-smokers, cardiovascular diseases. metabolic syndrome, obesity * for healthy participants with normal weight, inclusion criteria bmi25, age ≥18, non-smokers exclusion criteria: * for all participants were cancer, inflammatory diseases, tuberculosis, renal and hepatic insufficiency, and pregnancy * for healthy participants without cardiovascular diseases, obesity and metabolic syndrome
study of netarsudil ophthalmic solution in subjects with primary open angle glaucoma (poag) or ocular hypertension (oht)

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension

Summary: to evaluate the effect on trabecular outflow facility of netarsudil ophthalmic solution 0.02% compared to placebo

trabecular outflow facility is a measure of aqueous humor dynamics; effect of netarsudil on this parameter as well as on intraocular pressure and episcleral venous pressure was evaluated in this study. netarsudil treatment was given in one eye and placebo given in contralateral eye for 7 consecutive days.

Eligibility criteria:
inclusion criteria: 1. must be 18 years of age or older 2. diagnosis of open primary angle glaucoma(poag) or ocular hypertension (oht) in both eyes 3. unmedicated intraocular pressure (iop) \>20 mmhg and \< 30 mmhg in both eyes at first qualification visit 4. best corrected visual acuity (bcva) equivalent to 20/200 snellen or better 5. able to give informed consent and follow study instructions exclusion criteria: ophthalmic: 1. clinically significant ocular disease 2. pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles 3. intraocular pressure ≥30 mmhg in either eye 4. a difference in iop between eyes \>4mmhg at qualification visit 5. use of more than two ocular hypotensive medications within 30 days of screening 6. known hypersensitivity to any component of the formulation 7. previous glaucoma surgery or refractive surgery 8. keratorefractive surgery in either eye 9. report of ocular injury in either eye within the six months prior to screening or ocular or non-refractive surgery within 3 months prior to screening 10. recent or current ocular infection or inflammation in either eye 11. use of ocular medication in either eye of any kind within 30 days of screening 12. mean central corneal thickness greater than 620 μm in either eye 13. any abnormality preventing reliable applanation tonometry of either eye 14. lack of suitable episcleral vein prior to performing episcleral venus pressure (evp) measurement (applicable to 1 site only) systemic: 15. clinically significant abnormalities within 6 weeks prior to screening 16. clinically significant systemic disease 17. participation in any investigational study within 60 days prior to screening 18. use of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening 19. women of childbearing potential who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

Keywords: aqueous humor dynamics trabecular outflow netarsudil
radiological classification of the facial nerve

Conditions: Severe to Profound Sensorineural Hearing Loss; Undergoing Cochlear Implant Surgery

Summary: cortical mastoidectomy and posterior tympanotomy is a classic approach for cochlear implant. intimate knowledge of the relevant surgical anatomy of the temporal bone and facial recess is important to safely perform the posterior tympanotomy. anatomical variation of facial nerve such as lateral or anterior position of vertical segment of facial nerve, will render this approach challenging. in this research, investigators proposed a radiological classification system of the position of vertical segment of facial nerve in relation to the lateral semicircular canal to predict difficult cases with narrow facial recess.

cochlear implantation done by mastoidectomy, posterior tympanotomy and round window membrane insertion or cochleostomy, if we have to. in cases with very laterally placed vertical segment of the facial nerve a trans- mastoid trans- attic approach used with trans canal monitoring as an alternative approach. position of the vertical segment of the facial nerve (vfn) determined by coronal view hrct of temporal bone, bone window of 0.6 mm thickness by using the cut posterior to the internal auditory canal at the level of lateral semicircular canal (lscc) and then drawing a line parallel to the bony canal of the vfn and another parallel line on the outer bony wall of lateral semicircular canal (lscc), and comparing level of both. the location of the facial nerve classified into normal if the fn is medial, same level or lateral to lscc . investigators referred the laterally placed fn (lpfn) when the whole vertical segment of facial nerve is lateral to lscc. in addition, distance between vfn and lscc was measured in cases of laterally placed fn. investigators proposed a radiological classification system of the mastoid segment of facial nerve to predict round window niche accessibility through posterior tympanotomy pre-operatively by using coronal view computed tomography scan of temporal bone. facial nerve position classified into 3 types in relation to lscc: 1. type i medial to lscc 2. type ii same level of lscc 3. type iii laterally placed to lscc iii a) less than 2mm iii b) more than 2mm

Eligibility criteria:
inclusion criteria: * all patient who underwent cochlear implant surgery with preoperative computed tomography scan and high resolution ct scan of temporal bone exclusion criteria: * none
study to evaluate tnx-601 er monotherapy versus placebo in patients with major depressive disorder (mdd)

Conditions: Depression; Depressive Disorder; Depressive Symptoms; Depressive Disorder, Major; Depressive Episode; Depression Severe

Summary: this is a phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of tnx-601 er monotherapy versus placebo in patients with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * female or male aged 18 to 65 years (inclusive). * have a primary dsm-5 diagnosis of current mdd. 1. the duration of the current mde must be at least 12 weeks. 2. without psychotic or catatonic features. exclusion criteria: * psychiatric history: 1. diagnosis of dsm-5-defined lifetime bipolar disorder (i, ii, or unspecified), schizophrenia, schizoaffective disorder, mdd with psychotic features, other psychotic disorder, or antisocial personality disorder; current (past month) obsessive-compulsive disorder; current (past month) posttraumatic stress disorder; current (past 3 months) anorexia nervosa; lifetime opioid or lifetime sedative-hypnotic use disorders, as confirmed by the mini 7.0.2. 2. diagnosis of borderline personality disorder 3. patients with comorbid generalized anxiety disorder (gad), social anxiety disorder (sad), or panic disorder are excluded only if the gad, sad, or panic disorder is considered the primary psychiatric diagnosis, rather than mdd. (if mdd is the primary diagnosis, patients with comorbid gad, sad, and panic disorder are allowed for randomization). * patients with treatment refractory mdd, ie, previously having in their lifetime failed ≥2 treatments with at least 2 different classes of antidepressants of adequate dose, duration, and treatment adherence